STRATA pre-announces Q2 revenue $8.0M-$8.4M; XTRAC base down, TheraClear X up

STRATA Skin Sciences, Inc.

2024-Q2 EPS reported -$0.99 revenue$15,189,000

Preliminary Q2 2024 total revenue range: $8.0M - $8.4M.
Domestic XTRAC installed base fell from 907 (Q1) to 881 (Q2) per device realignment.
TheraClear X installed base grew from 104 (Q1) to 117 (Q2).
Cash, cash equivalents, and restricted cash totaled $6.8M at quarter end.
Full Q2 2024 results expected to be reported on August 14, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.